IMU Biosciences
Decoding the immune system to pioneer a paradigm shift in disease diagnosis and treatment.
About
IMU Biosciences is a biotechnology company developing "HD Immunology" by decoding the immune system with unprecedented resolution and scale. Their core offering is a multi-omic platform that generates over 100 million immune data points from 2ml of blood, resolving 2,500 discrete immune cell subsets in real-time to build the world's largest immune dataset. This platform powers precision medicine initiatives, including predictive screening tools for Hematopoietic Stem Cell Transplantation and graft rejection in Solid Organ Transplantation.
Key facts
- Website
- imubiosciences.com
- Headquarters
- London, England, United Kingdom
- Total funding
- $53M (Series A)
- Valuation
- Private
- Business model
- B2B
- Tags
- BiotechnologyArtificial IntelligenceHealthTechDrug DiscoveryBiotech
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 2 Jun 2026 | Series A | $53M | IQ Capital, Molten Ventures |
Tech stack
Detected on imubiosciences.com, last scanned 18 Sept 2026. Run your own scan
- CMS / Builders
- Framer
- Email provider
- Google Workspace
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Frequently asked
How much funding has IMU Biosciences raised?
IMU Biosciences has raised a total of $53M in funding. The most recent round on record is Series A.